Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE) 33% HIGHER; announced positive top-line results from clinical trials in treatment and prevention of Alzheimer’s disease as part of the collaboration with Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies. The two Phase 1 clinical trials of BI1181181/VTP-37948, an orally active beta secretase (BACE) inhibitor discovered by Vitae and developed by Boehringer Ingelheim, are randomized, placebo-controlled single dose studies (a single rising dose and a proof of mechanism study) that involved a total of 68 healthy volunteers.
The Rubicon Project (NYSE: RUBI) 19% HIGHER; reported Q3 EPS of $0.05, $0.22 better than